ReviewFrontiers in immunology2026
Immune-neural crosstalk in chronic low back pain: from intervertebral disc degeneration to pain sensitization.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic low back pain (CLBP) is a leading cause of disability, yet radiographic degeneration correlates poorly with symptoms. This mini-review examines how immune-neural crosstalk may link intervertebral disc degeneration to pain initiation and persistence. Degenerated nucleus pulposus and annulus fibrosus cells develop inflammatory and catabolic phenotypes and release mediators that may promote neural and vascular ingrowth, sensitize nociceptors, and increase dorsal root ganglion neuron excitability. Sustained peripheral input may engage spinal glial pathways and contribute to central sensitization. Pain may persist through expectation, learning, affective processes, and altered central prediction even when peripheral inflammatory input is limited. These interactions are bidirectional: immune signaling may affect mood, cognition, sleep, and threat processing, whereas stress, pain-related beliefs, and social context may modify immune and neural responses through autonomic and neuroendocrine pathways. Vertebral endplate inflammation, sometimes reflected by Modic type I changes, may mark an immune-associated phenotype. Although mechanistic and preclinical evidence supports targets such as NGF and pro-inflammatory cytokines, clinical benefit has been inconsistent, potentially because of safety concerns, patient heterogeneity, insufficient target engagement, and trial-design limitations. We propose a systems framework integrating inflammatory biomarkers, endplate imaging, quantitative sensory testing, neuroimmune imaging, and contextual measures. This framework may help distinguish inflammation-dominant, peripherally sensitized, central-sensitization-associated, nociplastic (pain arising from altered nociception), and mixed profiles. Validation requires prospective longitudinal studies, biomarker-stratified cohorts, and adequately powered randomized controlled trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.